By over 60% Surface Oncology (NASDAQ: SURF) surges right after the market’s opening. It is surely caused by disclosing the teaming up with Merck (NYSE: MRK) to evaluate Surf’s immuno-oncology SRF617 which targets the tumor microenvironment. Actually, the stock started rising yesterday by $0.649. But drastic change happened today as the market opened. Before this major move the stock price was almost flat if one considers in weekly changes. From the mid of December 2019, SURF could rise to $3.85 but then it fell to $1.67 on March 16.
Q1 2020 revenue and earnings have faced seriously positive changes by removing “minus” sign before the net income of common stockholders. This news could also be a vital game-changer in attracting new stock buyers.
CEO and Editor in Chief.
Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life